Ironwood Pharmaceuticals Inc (IRWD)vsViatris Inc (VTRS)
IRWD
Ironwood Pharmaceuticals Inc
$4.08
+2.77%
HEALTHCARE · Cap: $728.71M
VTRS
Viatris Inc
$16.51
+0.79%
HEALTHCARE · Cap: $19.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 3685% more annual revenue ($14.74B vs $389.32M). IRWD leads profitability with a 33.4% profit margin vs -2.8%. IRWD earns a higher WallStSmart Score of 69/100 (B-).
IRWD
Strong Buy69
out of 100
Grade: B-
VTRS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.9%
Fair Value
$33.87
Current Price
$4.08
$29.79 discount
Margin of Safety
-85.0%
Fair Value
$8.72
Current Price
$16.51
$7.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 70.2%
Revenue surging 32.6% year-over-year
Earnings expanding 125.7% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
ROE of -575.0% — below average capital efficiency
Distress zone — elevated risk
4.9% revenue growth
ROE of -2.9% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : IRWD
The strongest argument for IRWD centers on P/E Ratio, Profit Margin, Operating Margin. Profitability is solid with margins at 33.4% and operating margin at 70.2%. Revenue growth of 32.6% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.
Bear Case : IRWD
The primary concerns for IRWD are Market Cap, Return on Equity, Altman Z-Score.
Bear Case : VTRS
The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.
Key Dynamics to Monitor
IRWD profiles as a growth stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.88 — expect wider price swings.
IRWD is growing revenue faster at 32.6% — sustainability is the question.
VTRS generates stronger free cash flow (329M), providing more financial flexibility.
Bottom Line
IRWD scores higher overall (69/100 vs 48/100), backed by strong 33.4% margins and 32.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ironwood Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?